TY - JOUR
T1 - Temporal correlation between postreperfusion complement deposition and severe primary graft dysfunction in lung allografts
AU - Cerier, Emily
AU - Kurihara, Chitaru
AU - Kaiho, Taisuke
AU - Toyoda, Takahide
AU - Manerikar, Adwaiy
AU - Kandula, Viswajit
AU - Thomae, Benjamin
AU - Yagi, Yuriko
AU - Yeldandi, Anjana
AU - Kim, Samuel
AU - Avella Patino, Diego Mauricio
AU - Pandolfino, John
AU - Perlman, Harris
AU - Singer, Benjamin
AU - Scott Budinger, G. R.
AU - Lung, Kalvin
AU - Alexiev, Borislav
AU - Bharat, Ankit
N1 - Publisher Copyright:
© 2023 American Society of Transplantation & American Society of Transplant Surgeons
PY - 2024/4
Y1 - 2024/4
N2 - Growing evidence implicates complement in the pathogenesis of primary graft dysfunction (PGD). We hypothesized that early complement activation postreperfusion could predispose to severe PGD grade 3 (PGD-3) at 72 hours, which is associated with worst posttransplant outcomes. Consecutive lung transplant patients (n = 253) from January 2018 through June 2023 underwent timed open allograft biopsies at the end of cold ischemia (internal control) and 30 minutes postreperfusion. PGD-3 at 72 hours occurred in 14% (35/253) of patients; 17% (44/253) revealed positive C4d staining on postreperfusion allograft biopsy, and no biopsy-related complications were encountered. Significantly more patients with PGD-3 at 72 hours had positive C4d staining at 30 minutes postreperfusion compared with those without (51% vs 12%, P < .001). Conversely, patients with positive C4d staining were significantly more likely to develop PGD-3 at 72 hours (41% vs 8%, P < .001) and experienced worse long-term outcomes. In multivariate logistic regression, positive C4d staining remained highly predictive of PGD-3 (odds ratio 7.92, 95% confidence interval 2.97-21.1, P < .001). Hence, early complement deposition in allografts is highly predictive of PGD-3 at 72 hours. Our data support future studies to evaluate the role of complement inhibition in patients with early postreperfusion complement activation to mitigate PGD and improve transplant outcomes.
AB - Growing evidence implicates complement in the pathogenesis of primary graft dysfunction (PGD). We hypothesized that early complement activation postreperfusion could predispose to severe PGD grade 3 (PGD-3) at 72 hours, which is associated with worst posttransplant outcomes. Consecutive lung transplant patients (n = 253) from January 2018 through June 2023 underwent timed open allograft biopsies at the end of cold ischemia (internal control) and 30 minutes postreperfusion. PGD-3 at 72 hours occurred in 14% (35/253) of patients; 17% (44/253) revealed positive C4d staining on postreperfusion allograft biopsy, and no biopsy-related complications were encountered. Significantly more patients with PGD-3 at 72 hours had positive C4d staining at 30 minutes postreperfusion compared with those without (51% vs 12%, P < .001). Conversely, patients with positive C4d staining were significantly more likely to develop PGD-3 at 72 hours (41% vs 8%, P < .001) and experienced worse long-term outcomes. In multivariate logistic regression, positive C4d staining remained highly predictive of PGD-3 (odds ratio 7.92, 95% confidence interval 2.97-21.1, P < .001). Hence, early complement deposition in allografts is highly predictive of PGD-3 at 72 hours. Our data support future studies to evaluate the role of complement inhibition in patients with early postreperfusion complement activation to mitigate PGD and improve transplant outcomes.
KW - lung allografts
KW - lung transplant
KW - primary graft dysfunction
UR - http://www.scopus.com/inward/record.url?scp=85178594928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178594928&partnerID=8YFLogxK
U2 - 10.1016/j.ajt.2023.11.006
DO - 10.1016/j.ajt.2023.11.006
M3 - Article
C2 - 37977230
AN - SCOPUS:85178594928
SN - 1600-6135
VL - 24
SP - 577
EP - 590
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 4
ER -